Articles

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2

University of Rochester, NY, USA
Medical University of Lodz, Poland
Tom Baker Cancer Centre, Calgary, AB, Canada
ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel;Sackler Faculty of Medicine, Tel Aviv University, Israel
Washington University School of Medicine, St. Louis, MO, USA
University of Texas MD Anderson Cancer Center, Houston, TX, USA
The Leeds Teaching Hospitals, St. James Institute of Oncology, UK
Stanford University School of Medicine, CA, USA
Kings College Hospital, NHS Foundation Trust, London, UK
School of Public Health, Silesian Medical University, Katowice, Poland
Royal Bournemouth Hospital, UK
Jiangsu Province Hospital, Nanjing, China
North Shore Hospital, Auckland, New Zealand
Universitair Ziekenhuis Gent, Belgium
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Pharmacyclics, LLC, an AbbVie Company, Sunnyvale, CA, USA
Pharmacyclics, LLC, an AbbVie Company, Sunnyvale, CA, USA
Pharmacyclics, LLC, an AbbVie Company, Sunnyvale, CA, USA
University of California, San Diego, Moores Cancer Center, La Jolla, CA, USA
Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele, Milan, Italy
Vol. 103 No. 9 (2018): September, 2018 https://doi.org/10.3324/haematol.2018.192328